Northwest Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020
January 15, 2021 at 06:03 am EST
Share
Northwest Biotherapeutics, Inc. announced earnings results for the third quarter ended September 30, 2020. For the third quarter, the company announced total revenue was USD 216,000 compared to USD 593,000 a year ago. Operating loss was USD 47.877 million compared to USD 6.585 million a year ago. Net loss was USD 194.096 million compared to USD 6.371 million a year ago. Basic loss per share from continuing operations was USD 0.26 compared to USD 0.01 a year ago. For the nine months, total revenue was USD 788,000 compared to USD 1.513 million a year ago. Operating loss was USD 63.246 million compared to USD 21.247 million a year ago. Net loss was USD 249.522 million compared to USD 27.357 million a year ago. Basic loss per share from continuing operations was USD 0.36 compared to USD 0.05 a year ago.
Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct, is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and included treatment of a diverse range of more than a dozen types of cancers. The Companyâs wholly owned subsidiaries include Flaskworks, LLC, Northwest Biotherapeutics Limited, Aracaris Capital, Ltd, Northwest Biotherapeutics B.V., and NW Bio GmbH.
NORTHWEST BIOTHERAPEUTICS, INC. 
